View More View Less
  • 1 Semmelweis Egyetem, Általános Orvostudományi Kar, Budapest, Kútvölgyi út 4., 1125
  • | 2 Semmelweis Egyetem, Általános Orvostudományi Kar, Budapest
Open access

Cross Mark

Absztrakt:

Bevezetés: Az attenuált androgéneket gyakran alkalmazzák C1-inhibitor-hiányos hereditaer angiooedema akut epizódjainak megelőzésére. Praepubertason túli alkalmazásuk az epifízisfugák korai záródásához, ezáltal növekedés-visszamaradáshoz vezethet. Célkitűzés: A danazol hereditaer angiooedemás gyermekek hossznövekedésére kifejtett hatásának felmérése. Módszer: Retrospektív tanulmányunk negyvenkettő, 21 évesnél idősebb hereditaer angiooedemás beteg adatait elemezte. A betegek esetében meghatároztuk a várható testmagasságtól való eltérést, majd azt a betegek neme, valamint a 21 éves kor előtt végzett danazolkezelés összdózisa és időtartama függvényében elemeztük. Danazollal 16 éves kora előtt kezelt betegek esetében összefüggést kerestünk a várható testmagasságtól való eltérés, valamint a kezelés időtartama, illetve kumulatív dózisa között. Eredmények: Nem találtunk szignifikáns különbséget a várható testmagasságtól való eltérésben danazolt szedő/nem szedő, illetve fiú és leány betegek között. Ezt a különbséget a danazol dózisa és alkalmazásának időtartama 16 vagy 21 évesnél fiatalabb korban végzett kezelés esetén sem befolyásolta. Következtetések: A danazol a minimális hatékony dózisban alkalmazva nem befolyásolta a növekedést. Orv Hetil. 2017; 158(32): 1269–1276.

  • 1

    Cicardi M, Aberer W, Banerji A, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy 2014; 69: 602–616.

  • 2

    Kaplan AP, Ghebrehiwet B. The plasma bradykinin-forming pathways and its interrelationships with complement. Mol Immunol. 2010; 47: 2161–2169.

  • 3

    Cugno M, Cicardi M, Bottasso B, et al. Activation of the coagulation cascade in C1-inhibitor deficiencies. Blood 1997; 89: 3213–3218.

  • 4

    Zotter Z, Csuka D, Szabo E, et al. The influence of trigger factors on hereditary angioedema due to C1-inhibitor deficiency. Orphanet J Rare Dis. 2014; 9: 44.

  • 5

    Farkas H. Current pharmacotherapy of bradykinin-mediated angioedema. Expert Opin Pharmacother. 2013; 14: 571–586.

  • 6

    Ruzza P, Quintieri L, Osler A, et al. Fluorescent, internally quenched, peptides for exploring the pH-dependent substrate specificity of cathepsin B. J Pept Sci. 2006; 12: 455–461.

  • 7

    Mikkelsen TB, Osler M, Olsen SF. Validity of protein, retinol, folic acid and n-3 fatty acid intakes estimated from the food-frequency questionnaire used in the Danish National Birth Cohort. Public Health Nutr. 2006; 9: 771–778.

  • 8

    Lund R, Christensen U, Holstein BE, et al. Influence of marital history over two and three generations on early death. A longitudinal study of Danish men born in 1953. J Epidemiol Community Health 2006; 60: 496–501.

  • 9

    Kilgo PD, Meredith JW, Osler TM. Incorporating recent advances to make the TRISS approach universally available. J Trauma 2006; 60: 1002–1008; discussion 1008–1009.

  • 10

    Osler M, Petersen L, Prescott E, et al. Genetic and environmental influences on the relation between parental social class and mortality. Int J Epidemiol. 2006; 35: 1272–1277.

  • 11

    Cicardi M, Bork K, Caballero T, et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 2012; 67: 147–157.

  • 12

    Gelfand JA, Sherins RJ, Alling DW, et al. Treatment of hereditary angioedema with danazol: Reversal of clinical and biochemical abnormalities. N Engl J Med. 1976; 295: 1444–1448.

  • 13

    Pappalardo E, Zingale LC, Cicardi M. Increased expression of C1-inhibitor mRNA in patients with hereditary angioedema treated with Danazol. Immunol Lett. 2003; 86: 271–276.

  • 14

    Szeplaki G, Varga L, Valentin S, et al. Adverse effects of danazol prophylaxis on the lipid profiles of patients with hereditary angioedema. J Allergy Clin Immunol. 2005; 115: 864–869.

  • 15

    Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy Asthma Immunol. 2008; 100: 153–161.

  • 16

    Naets JP, Wittek M. Mechanism of action of androgens on erythropoiesis. Am J Physiol. 1966; 210: 315–320.

  • 17

    Kőhalmi KV, Veszeli N, Zotter Z, et al. The effect of long-term danazol treatment on haematological parameters in hereditary angioedema. Orphanet J Rare Dis. 2016; 11: 18.

  • 18

    Zotter Z, Veszeli N, Csuka D, et al. Frequency of the virilising effects of attenuated androgens reported by women with hereditary angioedema. Orphanet J Rare Dis. 2014; 9: 205.

  • 19

    Sheffer AL, Fearon DT, Austen KF. Clinical and biochemical effects of impeded androgen (oxymetholone) therapy of hereditary angioedema. J Allergy Clin Immunol. 1979; 64: 275–280.

  • 20

    Hosea SW, Santaella ML, Brown EJ, et al. Long-term therapy of hereditary angioedema with danazol. Ann Intern Med. 1980; 93: 809–812.

  • 21

    Uzych L. Anabolic-androgenic steroids and psychiatric-related effects: a review. Can J Psychiatry 1992; 37: 23–28.

  • 22

    Woodard TL, Burghen GA, Kitabchi AE, et al. Glucose intolerance and insulin resistance in aplastic anemia treated with oxymetholone. J Clin Endocrinol Metab. 1981; 53: 905–908.

  • 23

    Cohen JC, Hickman R. Insulin resistance and diminished glucose tolerance in powerlifters ingesting anabolic steroids. J Clin Endocrinol Metab. 1987; 64: 960–963.

  • 24

    Martikainen H, Alen M, Rahkila P, et al. Testicular responsiveness to human chorionic gonadotrophin during transient hypogonadotrophic hypogonadism induced by androgenic/anabolic steroids in power athletes. J Steroid Biochem. 1986; 25: 109–112.

  • 25

    Shahidi NT. A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids. Clin Ther. 2001; 23: 1355–1390.

  • 26

    Craig T, Aygoren-Pursun E, Bork K, et al. WAO guideline for the management of hereditary angioedema. World Allergy Organ J. 2012; 5: 182–199.

  • 27

    Bowen T. Hereditary angioedema: beyond international consensus – circa December 2010 – The Canadian Society of Allergy and Clinical Immunology Dr. David McCourtie Lecture. Allergy Asthma Clin Immunol. 2011; 7: 1.

  • 28

    Farkas H, Varga L. The Hungarian HAE experience. Transfus Apher Sci. 2003; 29: 229–233.

  • 29

    Tambalis KD, Panagiotakos DB, Arnaoutis G, et al. Establishing cross-sectional curves for height, weight, body mass index and waist circumference for 4- to 18-year-old Greek children, using the Lambda Mu and Sigma (LMS) statistical method. Hippokratia 2015; 19: 239–248.

  • 30

    Osler M. Estrogens and liver diseases. Ugeskr Laeger 1974; 136: 212.

  • 31

    Smith CS, Harris F. The role of danazol in the management of precocious puberty. Postgrad Med J. 1979; 55(Suppl 5): 81–86.

  • 32

    Lee PA, Thompson RG, Migeon CJ, et al. The effect of danazol in sexual precocity. Johns Hopkins Med J. 1975; 137: 265–269.

  • 33

    Keele DK, Worley JW. Study of an anabolic steroid. Certain effects of oxymetholone on small children. Am J Dis Child. 1967; 113: 422–430.

  • 34

    Sobel EH, Raymond CS, Quinn KV, et al. The use of methyltestosterone to stimulate growth: relative influence on skeletal maturation and linear growth. J Clin Endocrinol Metab. 1956; 16: 241–248.

  • 35

    Zuckerman-Levin N, Frolova-Bishara T, Militianu D, et al. Androgen replacement therapy in Turner syndrome: a pilot study. J Clin Endocrinol Metab. 2009; 94: 4820–4827.

  • 36

    Verver EJ, Freriks K, Sas TC, et al. Karyotype-specific ear and hearing problems in young adults with Turner syndrome and the effect of oxandrolone treatment. Otol Neurotol. 2014; 35(9): 1577–1584.

  • 37

    Davenport ML. Growth hormone therapy in Turner syndrome. Pediatr Endocrinol Rev. 2012; 9(Suppl 2): 723–724.

  • 38

    Karastaneva A, Lanz S, Wawer A, et al. Immune thrombocytopenia in two unrelated Fanconi anemia patients – A mere coincidence? Front Pediatr. 2015; 3: 50.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 68 62 4
PDF Downloads 79 73 1